1例用美泊利单抗成功治疗的慢性嗜酸性粒细胞性肺炎病例。 - Suppr

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

作者信息

To Masako, Kono Yuta, Yamawaki Satoshi, Soeda Seiko, Katsube Otohiro, Kishi Hirohisa, To Yasuo

机构信息

Department of Allergy and Respiratory Medicine, Fraternity Memorial Hospital, Yokoami, Sumida, Tokyo, Japan; Department of Laboratory Medicine, Dokkyo Medical University, Saitama Medical Center, Minami-Koshigaya, Koshigaya City, Saitama, Japan.

Department of Allergy and Respiratory Medicine, Fraternity Memorial Hospital, Yokoami, Sumida, Tokyo, Japan.

出版信息

J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1746-1748.e1. doi: 10.1016/j.jaip.2018.06.017. Epub 2018 Jul 7.

DOI:10.1016/j.jaip.2018.06.017

PMID:30201098

Abstract

摘要

相似文献

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1746-1748.e1. doi: 10.1016/j.jaip.2018.06.017. Epub 2018 Jul 7.

Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.

J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):154-155. doi: 10.18176/jiaci.0468. Epub 2019 Nov 28.

Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.

Ann Allergy Asthma Immunol. 2018 Jul;121(1):121-123. doi: 10.1016/j.anai.2018.04.016. Epub 2018 Apr 21.

Benralizumab as initial treatment for chronic eosinophilic pneumonia.

Allergol Int. 2021 Jan;70(1):140-142. doi: 10.1016/j.alit.2020.07.005. Epub 2020 Aug 14.

Mepolizumab use: Post-approval academic practice experience.

Ann Allergy Asthma Immunol. 2018 Jul;121(1):126-128. doi: 10.1016/j.anai.2018.04.001. Epub 2018 Apr 10.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017.

Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?

Lancet. 2016 Oct 29;388(10056):2059-2060. doi: 10.1016/S0140-6736(16)31537-9. Epub 2016 Sep 5.

Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.

J Investig Allergol Clin Immunol. 2021 Oct 25;31(5):459-460. doi: 10.18176/jiaci.0671. Epub 2021 Jan 27.

Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab.

Ann Allergy Asthma Immunol. 2021 Jun;126(6):726-727. doi: 10.1016/j.anai.2021.02.016. Epub 2021 Feb 24.

Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.

J Asthma. 2020 May;57(5):521-524. doi: 10.1080/02770903.2019.1579833. Epub 2019 Feb 22.

引用本文的文献

The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].

J Thorac Dis. 2025 Apr 30;17(4):1807-1831. doi: 10.21037/jtd-2024-2092. Epub 2025 Mar 25.

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?

Respir Med Case Rep. 2024 Nov 13;52:102142. doi: 10.1016/j.rmcr.2024.102142. eCollection 2024.

Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review.

BMC Pulm Med. 2024 Feb 8;24(1):74. doi: 10.1186/s12890-024-02868-3.

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia.

F1000Res. 2023 Sep 5;12:337. doi: 10.12688/f1000research.130939.2. eCollection 2023.

Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis.

Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(2):e2022020. doi: 10.36141/svdld.v39i2.12656. Epub 2022 Jun 29.

Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

J Asthma Allergy. 2022 Feb 9;15:169-177. doi: 10.2147/JAA.S343272. eCollection 2022.

Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of Chronic Eosinophilic Pneumonia and Allergic Bronchopulmonary Aspergillosis - Case series, Almoosa specialist hospital.

Respir Med Case Rep. 2021 Oct 1;34:101520. doi: 10.1016/j.rmcr.2021.101520. eCollection 2021.

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance.

Drugs Context. 2020 Aug 18;9. doi: 10.7573/dic.2020-5-3. eCollection 2020.

Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia.

Biomolecules. 2020 Apr 21;10(4):638. doi: 10.3390/biom10040638.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

Lung. 2020 Apr;198(2):355-360. doi: 10.1007/s00408-020-00336-3. Epub 2020 Feb 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

作者信息

To Masako, Kono Yuta, Yamawaki Satoshi, Soeda Seiko, Katsube Otohiro, Kishi Hirohisa, To Yasuo

机构信息

Department of Allergy and Respiratory Medicine, Fraternity Memorial Hospital, Yokoami, Sumida, Tokyo, Japan.

出版信息

J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1746-1748.e1. doi: 10.1016/j.jaip.2018.06.017. Epub 2018 Jul 7.

DOI:10.1016/j.jaip.2018.06.017

PMID:30201098

Abstract

摘要

相似文献

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1746-1748.e1. doi: 10.1016/j.jaip.2018.06.017. Epub 2018 Jul 7.

Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.

J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):154-155. doi: 10.18176/jiaci.0468. Epub 2019 Nov 28.

Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.

Ann Allergy Asthma Immunol. 2018 Jul;121(1):121-123. doi: 10.1016/j.anai.2018.04.016. Epub 2018 Apr 21.

Benralizumab as initial treatment for chronic eosinophilic pneumonia.

Allergol Int. 2021 Jan;70(1):140-142. doi: 10.1016/j.alit.2020.07.005. Epub 2020 Aug 14.

Mepolizumab use: Post-approval academic practice experience.

Ann Allergy Asthma Immunol. 2018 Jul;121(1):126-128. doi: 10.1016/j.anai.2018.04.001. Epub 2018 Apr 10.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017.

Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?

Lancet. 2016 Oct 29;388(10056):2059-2060. doi: 10.1016/S0140-6736(16)31537-9. Epub 2016 Sep 5.

Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.

J Investig Allergol Clin Immunol. 2021 Oct 25;31(5):459-460. doi: 10.18176/jiaci.0671. Epub 2021 Jan 27.

Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab.

Ann Allergy Asthma Immunol. 2021 Jun;126(6):726-727. doi: 10.1016/j.anai.2021.02.016. Epub 2021 Feb 24.

Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.

J Asthma. 2020 May;57(5):521-524. doi: 10.1080/02770903.2019.1579833. Epub 2019 Feb 22.

引用本文的文献

The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].

J Thorac Dis. 2025 Apr 30;17(4):1807-1831. doi: 10.21037/jtd-2024-2092. Epub 2025 Mar 25.

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?

Respir Med Case Rep. 2024 Nov 13;52:102142. doi: 10.1016/j.rmcr.2024.102142. eCollection 2024.

Monoclonal antibodies in idiopathic chronic eosinophilic pneumonia: a scoping review.

BMC Pulm Med. 2024 Feb 8;24(1):74. doi: 10.1186/s12890-024-02868-3.

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia.

F1000Res. 2023 Sep 5;12:337. doi: 10.12688/f1000research.130939.2. eCollection 2023.

Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis.

Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(2):e2022020. doi: 10.36141/svdld.v39i2.12656. Epub 2022 Jun 29.

Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series.

J Asthma Allergy. 2022 Feb 9;15:169-177. doi: 10.2147/JAA.S343272. eCollection 2022.

Respir Med Case Rep. 2021 Oct 1;34:101520. doi: 10.1016/j.rmcr.2021.101520. eCollection 2021.

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance.

Drugs Context. 2020 Aug 18;9. doi: 10.7573/dic.2020-5-3. eCollection 2020.

Possible Mechanisms of Eosinophil Accumulation in Eosinophilic Pneumonia.

Biomolecules. 2020 Apr 21;10(4):638. doi: 10.3390/biom10040638.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

Lung. 2020 Apr;198(2):355-360. doi: 10.1007/s00408-020-00336-3. Epub 2020 Feb 12.

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献